奥法妥木单抗与特立氟胺在不同种族/族裔复发型多发性硬化患者中的疗效:ASCLEPIOS I/II 亚组分析
ASCLEPIOS I/II 事后分析按种族/族裔比较奥法妥木单抗与特立氟胺治疗复发型多发性硬化患者的 NEDA-3 达成比例。0-24 月各亚组中奥法妥木单抗组 NEDA-3 比例均高于特立氟胺组,安全性与总体人群相似。
要点
- 非西班牙裔黑人亚组 NEDA-3:奥法妥木单抗 33.3% vs 特立氟胺 3.4%(OR 15.9,95%CI 1.67-151.71;p=0.0162)。
- 非西班牙裔亚裔亚组 NEDA-3:42.9% vs 21.9%(OR 3.18,95%CI 0.95-10.59;p=0.06)。
- 西班牙裔/拉丁裔亚组 NEDA-3:36.6% vs 18.6%(OR 3.21,95%CI 1.32-7.79;p=0.01)。
核心结论
- 在 ASCLEPIOS 试验各亚组中,奥法妥木单抗较特立氟胺与更高的 NEDA-3 达成比例相关。
研究设计与样本
- ASCLEPIOS I/II 为设计相同的双盲、双模拟、活性对照、多中心 3 期试验。
- 共纳入 1882 例复发型多发性硬化患者,按 1:1 随机接受奥法妥木单抗 20 mg 每 4 周一次或特立氟胺 14 mg 每日一次,最长 30 个月。
- 本分析为事后分析,按自我认定的种族/族裔(非西班牙裔黑人、非西班牙裔亚裔、西班牙裔/拉丁裔、非西班牙裔白人、其他/未知)分组。
主要发现
- 1882 例中,非西班牙裔黑人 64 例(3.4%)、非西班牙裔亚裔 71 例(3.8%)、西班牙裔/拉丁裔 145 例(7.7%)、非西班牙裔白人 1538 例(81.7%)。
- 0-24 月 NEDA-3 达成比例(奥法妥木单抗 vs 特立氟胺):非西班牙裔黑人 33.3% vs 3.4%(OR 15.9,95%CI 1.67-151.71;p=0.0162)。
- 非西班牙裔亚裔 42.9% vs 21.9%(OR 3.18,95%CI 0.95-10.59;p=0.06)。
- 西班牙裔/拉丁裔 36.6% vs 18.6%(OR 3.21,95%CI 1.32-7.79;p=0.01)。
- 非西班牙裔白人 37.4% vs 16.6%(OR 3.57,95%CI 2.73-4.67;p<0.0001)。
关键数值与推荐
- NEDA-3 定义为 3 参数无疾病活动证据。
- 不良事件发生率在治疗组间及种族/族裔亚组间大体相似,未发现新的或非预期安全信号。
临床怎么用
- 各治疗组内,0-24 月 NEDA-3 达成比例在各亚组与总体汇总人群中相似。
- 奥法妥木单抗与特立氟胺均耐受良好。
- 作者认为未来多发性硬化试验应纳入种族多元化人群,以更好地指导治疗决策并改善真实世界患者结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Race and ethnicity may influence the efficacy of disease-modifying therapies in patients with multiple sclerosis (MS). Incidence of MS in ethnically diverse groups may be higher; however, these populations are under-represented in MS trials. This post hoc analysis compared the proportion of patients achieving 3-parameter no evidence of disease activity (NEDA-3) with ofatumumab vs teriflunomide in participants with relapsing MS (RMS) enrolled in the ASCLEPIOS I/II trials by race/ethnicity subgroup. METHODS: ASCLEPIOS I/II were identical, double-blind, double-dummy, active-controlled, multicenter, phase 3 trials. Participants were randomized (1:1) to receive ofatumumab 20 mg every 4 weeks or teriflunomide 14 mg once daily for up to 30 months. Pooled data were used to determine the efficacy/safety of ofatumumab vs teriflunomide in participants who self-identified as non-Hispanic Black, non-Hispanic Asian, Hispanic/Latino, or non-Hispanic White. Participants who did not self-identify into one of these groups were classified as other/unknown. RESULTS: Of the 1,882 participants, 64 (3.4%) self-identified as non-Hispanic Black, 71 (3.8%) as non-Hispanic Asian, 145 (7.7%) as Hispanic/Latino, and 1,538 (81.7%) as non-Hispanic White. Baseline participant demographics/characteristics were largely balanced across subgroups, aside from minor variations in sex, disease duration, and MRI lesions. From months 0 to 24, the proportion of ofatumumab vs teriflunomide-treated patients achieving NEDA-3 (odds ratio [95% CI]) was as follows: non-Hispanic Black, 33.3% vs 3.4% (15.9 [1.67-151.71; p = 0.0162]); non-Hispanic Asian, 42.9% vs 21.9% (3.18 [0.95-10.59; p = 0.06]); Hispanic/Latino, 36.6% vs 18.6% (3.21 [1.32-7.79; p = 0.01]); and non-Hispanic White, 37.4% vs 16.6% (3.57 [2.73-4.67; p < 0.0001]). Rates of AEs were generally similar between treatment groups and across race/ethnicity subgroups; no new or unexpected safety signals were identified. DISCUSSION: Ofatumumab was associated with greater proportions of NEDA-3 achievement than teriflunomide across race/ethnicity subgroups in the ASCLEPIOS trials. Within each treatment group, the proportion of patients achieving NEDA-3 from months 0 to 24 was similar across the subgroups and overall pooled population. Both ofatumumab and teriflunomide were well tolerated. Future MS trials should include ethnically diverse groups to better inform treatment decisions and improve real-world patient outcomes. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov: NCT02792218 (clinicaltrials.gov/ct2/show/NCT02792218), NCT02792231 (clinicaltrials.gov/ct2/show/NCT02792231). Submission date: June 2, 2016. First enrollment: August 26, 2016. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that among patients aged 18-55 years with RMS, the improvement in NEDA-3 with ofatumumab was comparably better than with teriflunomide among patients self-identified as non-Hispanic Black, non-Hispanic Asian, non-Hispanic White, Hispanic/Latino, and other/unknown.
引用
- Williams MJ, Amezcua L, Cohan SL, et al. Efficacy of Ofatumumab and Teriflunomide in Patients With Relapsing MS From Racial/Ethnic Minority Groups: ASCLEPIOS I/II Subgroup Analyses. Neurology. 2024. PMID: 39018512. doi:10.1212/WNL.0000000000209610
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。